Immunotherapy Resistance of Lung Cancer

Overview

Journal Cancer Drug Resist

Date 2022 May 18

PMID 35582531

Authors

Xin Yu

Chaonan Han

Chunxia Su

Affiliations

Soon will be listed here.

Abstract

In recent years, immunotherapy has made remarkable breakthroughs and brought long-term survival benefits to lung cancer patients. However, a high percentage of patients do not respond to immunotherapy or their responses are transient, indicating the existence of immune resistance. Current studies show that the interactions between cancer cells and immune system are continuous and dynamic. A range of cancer cell-autonomous characteristics, tumor microenvironment factors, and host-related influences account for heterogenous responses. Furthermore, with the identification of new targets of immunotherapy and the development of immune-based combinations, we propose the response strategies to overcome resistance.

References

Herbst R, Baas P, Kim D, Felip E, Perez-Gracia J, Han J . Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2015; 387(10027):1540-1550. DOI: 10.1016/S0140-6736(15)01281-7. View

Reck M, Rodriguez-Abreu D, Robinson A, Hui R, Csoszi T, Fulop A . Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2016; 375(19):1823-1833. DOI: 10.1056/NEJMoa1606774. View

Anagnostou V, Smith K, Forde P, Niknafs N, Bhattacharya R, White J . Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer. Cancer Discov. 2016; 7(3):264-276. PMC: 5733805. DOI: 10.1158/2159-8290.CD-16-0828. View

Dong Z, Zhang J, Liu S, Su J, Zhang C, Xie Z . EGFR mutation correlates with uninflamed phenotype and weak immunogenicity, causing impaired response to PD-1 blockade in non-small cell lung cancer. Oncoimmunology. 2017; 6(11):e1356145. PMC: 5674946. DOI: 10.1080/2162402X.2017.1356145. View

Ready N, Farago A, De Braud F, Atmaca A, Hellmann M, Schneider J . Third-Line Nivolumab Monotherapy in Recurrent SCLC: CheckMate 032. J Thorac Oncol. 2018; 14(2):237-244. PMC: 8050700. DOI: 10.1016/j.jtho.2018.10.003. View

Ries C, Cannarile M, Hoves S, Benz J, Wartha K, Runza V . Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy. Cancer Cell. 2014; 25(6):846-59. DOI: 10.1016/j.ccr.2014.05.016. View

Li X, Wenes M, Romero P, Huang S, Fendt S, Ho P . Navigating metabolic pathways to enhance antitumour immunity and immunotherapy. Nat Rev Clin Oncol. 2019; 16(7):425-441. DOI: 10.1038/s41571-019-0203-7. View

Dong Z, Zhong W, Zhang X, Su J, Xie Z, Liu S . Potential Predictive Value of and Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma. Clin Cancer Res. 2017; 23(12):3012-3024. DOI: 10.1158/1078-0432.CCR-16-2554. View

Socinski M, Jotte R, Cappuzzo F, Orlandi F, Stroyakovskiy D, Nogami N . Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC. N Engl J Med. 2018; 378(24):2288-2301. DOI: 10.1056/NEJMoa1716948. View

10.

Dearden S, Stevens J, Wu Y, Blowers D . Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap). Ann Oncol. 2013; 24(9):2371-6. PMC: 3755331. DOI: 10.1093/annonc/mdt205. View

11.

Antonia S, Villegas A, Daniel D, Vicente D, Murakami S, Hui R . Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. N Engl J Med. 2017; 377(20):1919-1929. DOI: 10.1056/NEJMoa1709937. View

12.

Finotello F, Trajanoski Z . New strategies for cancer immunotherapy: targeting regulatory T cells. Genome Med. 2017; 9(1):10. PMC: 5273791. DOI: 10.1186/s13073-017-0402-8. View

13.

Gettinger S, Choi J, Hastings K, Truini A, Datar I, Sowell R . Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer. Cancer Discov. 2017; 7(12):1420-1435. PMC: 5718941. DOI: 10.1158/2159-8290.CD-17-0593. View

14.

Huang B, Pan P, Li Q, Sato A, Levy D, Bromberg J . Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer Res. 2006; 66(2):1123-31. DOI: 10.1158/0008-5472.CAN-05-1299. View

15.

Gaboriau-Routhiau V, Rakotobe S, Lecuyer E, Mulder I, Lan A, Bridonneau C . The key role of segmented filamentous bacteria in the coordinated maturation of gut helper T cell responses. Immunity. 2009; 31(4):677-89. DOI: 10.1016/j.immuni.2009.08.020. View

16.

Gao Y, Nihira N, Bu X, Chu C, Zhang J, Kolodziejczyk A . Acetylation-dependent regulation of PD-L1 nuclear translocation dictates the efficacy of anti-PD-1 immunotherapy. Nat Cell Biol. 2020; 22(9):1064-1075. PMC: 7484128. DOI: 10.1038/s41556-020-0562-4. View

17.

Lastwika K, Wilson 3rd W, Li Q, Norris J, Xu H, Ghazarian S . Control of PD-L1 Expression by Oncogenic Activation of the AKT-mTOR Pathway in Non-Small Cell Lung Cancer. Cancer Res. 2015; 76(2):227-38. DOI: 10.1158/0008-5472.CAN-14-3362. View

18.

Wang Z, Till B, Gao Q . Chemotherapeutic agent-mediated elimination of myeloid-derived suppressor cells. Oncoimmunology. 2017; 6(7):e1331807. PMC: 5543863. DOI: 10.1080/2162402X.2017.1331807. View

19.

Lin E, Nguyen A, Russell R, Pollard J . Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy. J Exp Med. 2001; 193(6):727-40. PMC: 2193412. DOI: 10.1084/jem.193.6.727. View

20.

Gainor J, Shaw A, Sequist L, Fu X, Azzoli C, Piotrowska Z . EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis. Clin Cancer Res. 2016; 22(18):4585-93. PMC: 5026567. DOI: 10.1158/1078-0432.CCR-15-3101. View